ADVERSE EFFECT OF ANDROGEN DEPRIVATION THERAPY ON METABOLIC SYNDROME AND ITS COMPONENTS IN METASTATIC PROSTATE CARCINOMA PATIENTS

Jain Priyanka¹, Jha Manju^1, , Sharma Sonali¹ and Bapna Ajay²

¹Department of Biochemistry, RUHS College of Medical Sciences, Jaipur, Rajasthan(India)

²Department of Medical Oncology, Bhagwan Mahaveer Cancer Hospital and Research Centre, Jaipur, Rajasthan (India).

Cite this paper:
Jain Priyanka, Jha Manju, Sharma Sonali and Bapna Ajay. ADVERSE EFFECT OF ANDROGEN DEPRIVATION THERAPY ON METABOLIC SYNDROME AND ITS COMPONENTS IN METASTATIC PROSTATE CARCINOMA PATIENTS. International Journal of Clinical and Diagnostic Research. 2019; 7(6):141-153. doi: 10.12691/ijcdr-7-6-3

Abstract

Objective: Study was done to investigate the adverse effects of androgen-deprivation therapy on metabolic syndrome and its components in metastatic prostate carcinoma patients. Material and Methods: It was a hospital-based prospective study comprising fifty-one subjects with diagnosed metastatic prostate carcinoma. The subjects receiving androgen deprivation therapy were classified into two groups, one group including patients who have received gonadotropin-releasing hormone (n=18) and another group including patients with bilateral orchiectomy (n=33) on the basis of the modalities of androgen deprivation therapy. Measurement of the anthropometric parameters viz. blood pressure, body weight, height, body mass index and biochemical parameters viz. fasting plasma glucose, fasting insulin, insulin resistance and insulin sensitivity, total lipids, phospholipids, total cholesterol, triglycerides, high density lipoprotein, low density lipoprotein and very low density lipoprotein cholesterol, free fatty acid, levels of testosterone and prostate-specific antigen were done and the subjects were examined for Adult Treatment Panel III (ATP-III) criteria for metabolic syndrome. Results: A significant rise was observed in the waist circumference and biochemical parameters and insulin sensitivity and also the level of testosterone and prostate-specific antigen were significantly decreased after the androgen deprivation therapy (i.e. orchiectomy and medical therapy) of 18 months. Conclusions: The results of the present study suggest that androgen deprivation therapy adversely affects the metabolic risk factors as identified by Adult Treatment Panel III and also increases the risk of diabetes and cardiovascular disease.

Keywords:
Prostate carcinoma Androgen deprivation therapy Metabolic syndrome Diabetes mellitus

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/